AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03726866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 5
Description: D326, D337 or CKD-828 for 9 days
Study NCT03726866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 6
Description: D326, D337 or CKD-828 for 9 days
Study NCT04349917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.
Study NCT04349917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.
Study NCT04349917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A matching placebo pill will be administered on the placebo day.
Study NCT04349917 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo pill will be administered on the placebo day.
Study NCT03116659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 100 mg PO BID x 14 days
Study NCT03116659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: up to 2 packs 3/ week x 28 days
Study NCT03584139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRIS HOOK
Description: iris hook assisted maneuver in phacoemulsification
Study NCT03584139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRADITION
Description: traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
Study NCT04008498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AEEG brain monitoring
Description: Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby.
Study NCT03557762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
Study NCT03557762 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
Study NCT01930227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS
Description: Electric stimulation was given through electrode attached to specific acupoints
Study NCT01930227 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-acupoint stimulation
Description: Electric stimulation was given through electrode attached to the shoulder
Study NCT02696694 — intervention group
Intervention type: OTHER
Intervention: Progesterone 25-75
Description: Impact of serum progesterone concentrations \[25-75\] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
Study NCT02696694 — intervention group
Intervention type: OTHER
Intervention: Progesterone <25, >75
Description: Impact of serum progesterone concentrations (\<25, >75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
Study NCT00641394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy: Emotional Freedom Techniques (EFT)
Description: A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
Study NCT00641394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
Study NCT03025945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.3%
Study NCT03025945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study NCT00857935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NatrOVA Creme Rinse - 1%
Description: NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
Study NCT00857935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIX Creme Rinse - 1% permethrin
Description: NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
Study NCT01159860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryosurgery
Description: freezing of lesion with liquid nitrogen
Study NCT01159860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage
Description: the lesion will be anesthetized and destroyed with a curette.
Study NCT02087514 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Transfusion
Description: A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
Study NCT02087514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Transfusion
Description: A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
Study NCT02087514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packed red blood cells
Description: Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks
Study NCT02087514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed red blood cells
Description: Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~* 1 week~* 2 weeks~* 3 weeks~* 4 weeks~* 5 weeks~* 6 weeks
Study NCT01667263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Study NCT01667263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Study NCT01956786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine-FA tablet,low dose group
Description: 5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
Study NCT01956786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine-FA tablet,high dose group
Description: 5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
Study NCT01956786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5mg amlodipine,once daily
Study NCT01590420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP S8- Scape / Resmed
Description: The pressure for treatment is according to PSG titration
Study NCT04234685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Physio Light Therapy (HIPL Therapy™)
Description: HIPL Therapy™ is an advanced phototherapy method that utilizes an emission wavelength spectrum that has been optimized for treatment of musculoskeletal disorders (MSD) such as OA.
Study NCT04234685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will take part in education on osteoarthritis, pain neurophysiology, and self-management strategies with the treating physiotherapist. The education will take place during the lab visits and will be brief (5-10 minutes at each session).
Study NCT04234685 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: Participants will take part in education on osteoarthritis, pain neurophysiology, and self-management strategies with the treating physiotherapist. The education will take place during the lab visits and will be brief (5-10 minutes at each session).
Study NCT04234685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will develop an individualized walking program. The goal will be to walk 30 minutes 5 times/week if able. For all participants who are unable to achieve this walking, they will be provided with a progressive walking program that starts at their baseline (the distance they can walk without being sore an hour later; and without feeling like they will be unable to perform their usual activities of daily living because of the walk). They will be encouraged to then progress by 10-20% each week. Participants will be asked to use a provided walking log to keep track of their progress.
Study NCT04234685 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants will develop an individualized walking program. The goal will be to walk 30 minutes 5 times/week if able. For all participants who are unable to achieve this walking, they will be provided with a progressive walking program that starts at their baseline (the distance they can walk without being sore an hour later; and without feeling like they will be unable to perform their usual activities of daily living because of the walk). They will be encouraged to then progress by 10-20% each week. Participants will be asked to use a provided walking log to keep track of their progress.
Study NCT04234685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will also be instructed how to perform a series of six exercises: squat, step-up, lunge, single leg stance, knee flexion/extension, and resisted hamstring curl. The exercise technique and dosage will be tailored to the individual's current abilities. For example, if someone is unable to squat down to the level of a chair and return to standing, the chair height will be raised until the participant is able to perform the activity. The participants will begin by being asked to complete one set of 8-12 repetitions of each exercise, once daily, then progress to two or three sets daily as able. They will perform the exercises twice/week in the lab where they will receive support for problem solving and progression. Participants will be asked to use a provided exercise log to keep track of their progress.
Study NCT04234685 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will also be instructed how to perform a series of six exercises: squat, step-up, lunge, single leg stance, knee flexion/extension, and resisted hamstring curl. The exercise technique and dosage will be tailored to the individual's current abilities. For example, if someone is unable to squat down to the level of a chair and return to standing, the chair height will be raised until the participant is able to perform the activity. The participants will begin by being asked to complete one set of 8-12 repetitions of each exercise, once daily, then progress to two or three sets daily as able. They will perform the exercises twice/week in the lab where they will receive support for problem solving and progression. Participants will be asked to use a provided exercise log to keep track of their progress.
Study NCT04234685 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Physio Light Therapy (HIPL Therapy™)
Description: Phototherapy delivered at an intensity of 5 mW/cm2, a dosage at which there is no therapeutic benefit expected, but the light will still be visible to the participant.
Study NCT00899483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose potassium insulin solution
Description: Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
Study NCT02925247 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adherence to oral anticoagulant treatment
Description: The adherence will be evaluated by biological results
Study NCT02388191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Description: 550 mg, oral, on day 1. Number of Cycles: 1
Study NCT02388191 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study NCT03824119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Standard postpartum care (including administration of NSAIDs)
Study NCT03824119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Postpartum Care without NSAIDs
Description: NSAID administration will be withheld from this group.
Study NCT01433718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular and Resistance Training
Description: 1 hour/session, 3 sessions/week, 6 weeks
Study NCT02350647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture Anchor HEALOCOIL
Description: Rotator cuff tears will be repaired intraoperatively using suture anchors
Study NCT02350647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture anchor Twinfix Ultra HA
Study NCT02356302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicriviroc (MK-4176) Intravaginal Ring (IVR)
Description: Contains 182 mg vicriviroc (MK-4176).
Study NCT02356302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MK-2048 IVR
Description: Contains 30 mg MK-2048.
Study NCT02356302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MK-2048A IVR
Description: Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.
Study NCT02356302 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IVR
Study NCT01873586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral Fusion
Study NCT01873586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterolateral Fusion
Study NCT02173418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phrenic nerve block with Ropivacaine
Study NCT02173418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phrenic nerve block with saline
Study NCT01108094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: * Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~* Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months
Study NCT01954394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Study NCT01954394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study NCT01312415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
Study NCT01312415 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intrathecal morphine
Description: Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
Study NCT03970421 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Check clinical status at different time intervals during 3 months
Study NCT00523263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Human umbilical vein femoro-popliteal bypass
Study NCT02610504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane
Description: single injection of 3ml
Study NCT03219710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
Study NCT03219710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
Study NCT03851250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRx-4DP0004
Description: Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
Study NCT03851250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomised to receive placebo will take it in addition to their regular asthma medication.
Study NCT01140581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRONEDARONE
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
Study NCT04025645 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MEASUREMENT OF COMMON BILE DUCT PRESSURES
Description: THE PRESSURES OF THE COMMON BILE DUCT WERE MEASURED
Study NCT00849901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30-120 mg, PO, QD, for up to 38 weeks
Study NCT00849901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
Study NCT00849901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 10-40 milligram (mg), PO, QD, for up to 38 weeks
Study NCT02172105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL
Study NCT02172105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01207986 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Low dose computed tomography (CT)
Study NCT05059249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: Superficial Heating
Study NCT05059249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Traction
Description: Manual Traction for 10 minutes
Study NCT05059249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Traction
Description: Mechanical Traction for 10 minutes
Study NCT05059249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions
Study NCT05059249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS for 10 minutes with hot pack
Study NCT05122208 — intervention group
Intervention type: DRUG
Intervention: Famotidine Tablets
Description: 160 mg/day Famotidine
Study NCT02883452 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks (Part 1)
Study NCT01926626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Study NCT02883452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (120 mg) by single SC injection every 2 weeks (Part 1)
Study NCT02883452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (180 mg) by double SC 90 mg injections every 2 weeks (Part 1)
Study NCT02883452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (240 mg) by double SC 120 mg injections every 2 weeks (Part 1)
Study NCT02883452 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 6 (Part 2)
Study NCT02883452 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks up to Week 22. From Week 30, CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 30 (Part 2)
Study NCT00020826 — intervention group
Intervention type: OTHER
Intervention: quality-of-life assessment
Description: QLQ-C30 questionnaire administered. STO22 questionnaire administered.
Study NCT00378131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC-1291
Study NCT00378131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03901768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.